Analysts’ Recent Ratings Changes for Dyne Therapeutics (DYN)

Dyne Therapeutics (NASDAQ: DYN) has recently received a number of price target changes and ratings updates:

• 12/15/2025 – Dyne Therapeutics had its price target lowered by analysts at Evercore ISI from $38.00 to $36.00. They now have an “outperform” rating on the stock.
• 12/11/2025 – Dyne Therapeutics had its price target raised by analysts at Stifel Nicolaus from $36.00 to $39.00. They now have a “buy” rating on the stock.
• 12/10/2025 – Dyne Therapeutics was upgraded by analysts at Oppenheimer Holdings, Inc. from a “market perform” rating to an “outperform” rating. They now have a $40.00 price target on the stock, up previously from $11.00.
• 12/9/2025 – Dyne Therapeutics was given a new $23.00 price target on by analysts at Tudor Pickering.
• 12/9/2025 – Dyne Therapeutics was given a new $23.00 price target on by analysts at Sanford C. Bernstein.
• 12/9/2025 – Dyne Therapeutics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $38.00 price target on the stock.
• 12/8/2025 – Dyne Therapeutics had its price target raised by analysts at Morgan Stanley from $46.00 to $50.00. They now have an “overweight” rating on the stock.
• 12/8/2025 – Dyne Therapeutics was given a new $30.00 price target on by analysts at Robert W. Baird.
• 12/8/2025 – Dyne Therapeutics had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 12/8/2025 – Dyne Therapeutics had its “strong-buy” rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $40.00 price target on the stock.
• 12/8/2025 – Dyne Therapeutics had its price target raised by analysts at HC Wainwright from $46.00 to $60.00. They now have a “buy” rating on the stock.
• 11/25/2025 – Dyne Therapeutics had its “market perform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $21.00 price target on the stock.
• 11/14/2025 – Dyne Therapeutics had its price target lowered by analysts at JPMorgan Chase & Co. from $18.00 to $17.00. They now have a “neutral” rating on the stock.
• 11/12/2025 – Dyne Therapeutics had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $13.00 to $11.00. They now have a “market perform” rating on the stock.
• 11/6/2025 – Dyne Therapeutics had its “outperform” rating reaffirmed by analysts at Evercore ISI. They now have a $38.00 price target on the stock.
• 11/6/2025 – Dyne Therapeutics had its price target raised by analysts at HC Wainwright from $38.00 to $46.00. They now have a “buy” rating on the stock.
• 11/6/2025 – Dyne Therapeutics had its price target raised by analysts at Royal Bank Of Canada from $23.00 to $30.00. They now have an “outperform” rating on the stock.

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.